. 2005 Mar 24;7(3):R644–R665. doi: 10.1186/ar1704

Table 8.

Endoscopically detected ulcers in patients treated for arthritis, with and without aspirin

			Number of		Incidence of events (%)
Outcome/ comparisons	Celecoxib daily dose	Comparator and daily dose	Trials	Patients	Celecoxib	Comparator	Relative risk^a(95% CI)	NNTp^bor NNH^c(95% CI)

*Analysis irrespective of aspirin use*

Celecoxib v placebo	Any	Placebo	2	1,737	3.9	2.2	1.8 (0.89–3.6)
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	6	4,135	4.6	16.3	0.30 (0.24–0.37)^a	8.6 (7.4–10)^b
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	6	4,565	4.5	16.3	0.29 (0.24–0.36)^a	8.4 (7.3–10)^b

*Analysis without aspirin use*

Celecoxib v placebo	Any	Placebo	2	1,537	3.3	1.9	1.8 (0.79–3.9)
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	5	3,053	4.5	17.6	0.28 (0.22–0.36)^a	7.6 (6.5–9.1)^b
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	5	3,440	4.2	17.6	0.28 (0.22–0.36)^a	7.5 (6.4–8.9)^b

*Analysis with aspirin use*

Celecoxib v placebo	Any	Placebo	2	200	7.9	4.1	1.7 (0.45–6.3)
Celecoxib (200/400) v NSAID	200–400 mg	NSAID to maximum daily	5	344	10.0	23.8	0.47 (0.27–0.83)^a	7.3 (4.6–17)^b
Celecoxib (any dose) v NSAID	Any	NSAID to maximum daily	5	387	9.9	23.8	0.48 (0.28–0.83)^a	7.2 (4.7–16)^b

^aRelative risk: bold indicates statistically significant difference. ^bNNTp (number-needed-to-treat to prevent one event) is indicated by bold. ^cNNH (number-needed-to-treat to harm one patient). CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug.